This content is in French.
Alzheimer’s disease: from symptomatic treatments to the first disease-modifying therapies
2 octobre 2026
For many
years, treatments for Alzheimer’s disease primarily focused on alleviating
symptoms, without affecting disease progression. The recent arrival of antibodies
targeting amyloid-beta therefore represents an important shift: for the
first time, treatments can slow cognitive and functional decline in the early
stages of the disease.
A review
published in Sage Open Aging in 2025 provides an update on this new
therapeutic approach, focusing on two antibodies now available in the United
States: lecanemab and donanemab. Beyond their efficacy, the review
highlights a key challenge: identifying patients who may benefit while
carefully managing treatment-related risks.
Sign in to read the rest
Reserved for healthcare professionals, free registration.
Scientific reference
Kovacik A, Vandergriff K, Jarrett B, Clevenger C. An Update of the Treatment Landscape for Alzheimer’s Disease: From Symptomatic Treatments to the Emergence of Amyloid-Targeting Therapies. Sage Open Aging. 2025;11:1–9. doi:10.1177/30495334251376614.
